1. Field Cancerization in Sporadic Colon Cancer
- Author
-
Kyu Yong Choi, Hyung Ook Kim, Kyung Eun Kim, Ho-Kyung Chun, Kyung Uk Jeong, Soo-Kyung Park, Hungdai Kim, Hyo-Joon Yang, Yoon Suk Jung, Dong Hoe Koo, Dong Il Park, and Chang Seok Song
- Subjects
Male ,0301 basic medicine ,Epigenomics ,Colon ,Colorectal cancer ,Muscle Proteins ,Bone Morphogenetic Protein 3 ,Nerve Tissue Proteins ,Biology ,Bone Morphogenetic Protein Receptors, Type II ,Polymerase Chain Reaction ,Colorectal neoplasms ,Field effect ,03 medical and health sciences ,0302 clinical medicine ,Biomarkers, Tumor ,medicine ,Humans ,Intestinal Mucosa ,Promoter Regions, Genetic ,education ,Gene ,Glycoproteins ,education.field_of_study ,DNA methylation ,Hepatology ,Gastroenterology ,Membrane Proteins ,Promoter ,Colonoscopy ,Methylation ,Middle Aged ,medicine.disease ,Molecular biology ,Tissue-factor-pathway inhibitor 2 ,030104 developmental biology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Cancer research ,Female ,Field cancerization ,Original Article ,Erratum - Abstract
BACKGROUND/AIMS Aberrant DNA methylation has a specific role in field cancerization. Certain molecular markers, including secreted frizzled-related protein 2 (SFRP2), tissue factor pathway inhibitor 2 (TFPI2 ), N-Myc downstream-regulated gene 4 (NDRG4) and bone morphogenic protein 3 (BMP3), have previously been shown to be hypermethylated in colorectal cancer (CRC). We aim to examine field cancerization in CRC based on the presence of aberrant DNA methylation in normal-appearing tissue from CRC patients. METHODS We investigated promoter methylation in 34 CRC patients and five individuals with normal colonoscopy results. CRC patients were divided into three tissue groups: tumor tissue, adjacent and nonadjacent normal-appearing tissue. The methylation status (positive: methylation level >20%) of SFRP2 , TFPI2 , NDRG4 , and BMP3 promoters was investigated using methylation-specific PCR. RESULTS The methylation frequencies of the SFRP2 , TFPI2 , NDRG4 and BMP3 promoters in tumor/adjacent/nonadjacent normal-appearing tissue were 79.4%/63.0%/70.4%, 82.4%/53.6%/60.7%, 76.5%/61.5%/69.2%, 41.2%/35.7%/50.0%, respectively. The methylation levels of the SFRP, TFPI2, NDRG4 and BMP3 promoters in tumor tissues were significantly higher than those in normal-appearing tissue (SFRP2, p=0.013; TFPI2, p
- Published
- 2016